Resource utilization of pediatric patients exposed to venom.

TitleResource utilization of pediatric patients exposed to venom.
Publication TypeJournal Article
Year of Publication2014
AuthorsNarra A, Lie E, Hall M, Macy ML, Alpern ER, Shah SS, Osterhoudt KC, Fieldston ES
JournalHosp Pediatr
Volume4
Issue5
Pagination276-82
Date Published2014 Sep
ISSN2154-1663
KeywordsAmbulatory Care, Antivenins, Child, Cost Sharing, Emergency Service, Hospital, Health Resources, Hospitalization, Hospitals, Pediatric, Humans, Length of Stay, Retrospective Studies, Snake Bites, United States
Abstract

BACKGROUND AND OBJECTIVE: Treating envenomation with antivenom is costly. Many patients being treated with antivenom are in observation status, a billing designation for patients considered to need care that is less resource-intensive, and less expensive, than inpatient care. Observation status is also associated with lower hospital reimbursements and higher patient cost-sharing. The goal of this study was to examine resource utilization for treatment of envenomation under observation and inpatient status, and to compare patients in observation status receiving antivenom with all other patients in observation status.

METHODS: This was a retrospective study of patients with a primary diagnosis of toxic effect of venom seen during 2009 at 33 freestanding children's hospitals in the Pediatric Health Information System. Data on age, length of stay, adjusted costs (ratio cost to charges), ICU flags, and antivenom utilization were collected. Comparisons were conducted according to admission status (emergency department only, observation status, and inpatient status), and between patients in observation status receiving antivenom and patients in observation status with other diagnoses.

RESULTS: A total of 2755 patients had a primary diagnosis of toxic effect of venom. Of the 335 hospitalized, either under observation (n = 124) or inpatient (n = 211) status, 107 (31.9%) received antivenom. Of those hospitalized patients receiving antivenom, 24 (22.4%) were designated as observation status. Costs were substantially higher for patients who received antivenom and were driven by pharmacy costs (mean cost: $17 665 for observation status, $20 503 for inpatient status). Mean costs for the 47 162 patients in observation status with other diagnoses were $3001 compared with $17 665 for observation-status patients who received antivenom.

CONCLUSIONS: Treatment of envenomation with antivenom represents a high-cost outlier within observation-status hospitalizations. Observation status can have financial consequences for hospitals and patients.

DOI10.1542/hpeds.2014-0010
Alternate JournalHosp Pediatr
PubMed ID25318109